AdipotidevsEcnoglutide

Adipotide uses a fundamentally different approach to fat reduction compared to appetite suppressants or metabolic modulators — it physically destroys the blood supply feeding white adipose tissue. The molecule is a chimeric peptidomimetic with two functional domains: a targeting peptide (sequence CKGGRAKDC) that homes to blood vessels in white fat, and a pro-apoptotic peptide (D(KLAKLAK)2) that kills the cells it enters.

The targeting sequence binds specifically to prohibitin, a protein expressed on the luminal surface of endothelial cells in the vasculature supplying white adipose tissue but not other organ systems. This vascular address system means adipotide accumulates selectively in fat tissue blood vessels. Once bound, the molecule is internalized into the endothelial cells, where the pro-apoptotic D(KLAKLAK)2 domain disrupts mitochondrial membrane integrity, triggering programmed cell death.

As the blood vessels supplying fat deposits are destroyed, the adipose tissue they serve undergoes ischemic cell death and is gradually reabsorbed by the body. In rhesus monkey studies, adipotide treatment produced significant reductions in body weight and waist circumference, with measurable decreases in white fat mass on imaging. However, the approach carries inherent risks — the targeting is not perfectly specific, and prohibitin expression in renal vasculature led to significant kidney toxicity in primate studies, which has severely limited clinical development.

Ecnoglutide is a long-acting GLP-1 receptor agonist engineered for once-weekly subcutaneous dosing using a structural design distinct from albumin-binding (semaglutide) or PEGylation. The molecule incorporates extended-half-life modifications that resist DPP-4 enzymatic degradation while maintaining high-affinity binding and full agonist activity at the GLP-1 receptor.

Receptor activation produces the standard GLP-1 pharmacology: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowed gastric emptying via vagal signalling, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. The clinical profile in Chinese Phase 3 trials closely mirrors semaglutide — approximately 14-15% body weight loss in obesity studies and substantial HbA1c reductions in type 2 diabetes trials — positioning ecnoglutide as a regional alternative to Wegovy and Ozempic with potentially lower pricing.

Ecnoglutide reflects a broader trend of Chinese biotech companies developing GLP-1 receptor agonists for both domestic and international markets. Sciwind Biosciences has filed for regulatory approval in China and is pursuing international development pathways. The molecule is one of several Chinese-developed GLP-1s approaching commercial launch alongside mazdutide, retatrutide-class triple agonists in early Chinese development, and a wave of biosimilar semaglutide products expected as patents expire in major markets through the late 2020s.